NYSE · Healthcare
HAEMONETICS CORP (HAE)
As-reported financials and recent SEC filings for HAEMONETICS CORP, latest fiscal period FY2026. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.33B
Net income
$97.3M
Net margin
7.3%
Diluted EPS
$2.05
ROE
12.2%
P/E (TTM)
37.7×
Market cap
$3.51B
Debt / equity
1.5×
Income statement (as reported)
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M |
| Gross profit | $787.6M | $749.0M | $691.5M | $615.1M | $505.5M |
| Operating income | $156.7M | $221.8M | $164.9M | $156.0M | $80.8M |
| Net income | $97.3M | $167.7M | $117.6M | $115.4M | $43.4M |
| Diluted EPS | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
ARS2026-06-09
View on EDGAR →DEFA14A2026-06-09
View on EDGAR →DEF 14A2026-06-09
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →8-K2026-06-05
View on EDGAR →SD2026-05-28
View on EDGAR →10-K2026-05-20
View on EDGAR →Go deeper on HAE
Search HAEMONETICS CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.